Biogen Idec, Abbott present efficacy data of DAC HYP in RRMS treatment Pharmaceutical Business Review Biogen Idec and Abbott have reported the additional results from the Select Phase 2b trial, which assessed the investigational compound daclizumab high-yield process (DAC HYP) to treat relapsing-remitting multiple sclerosis (RRMS). ... BIOGEN IDEC INC. : Biogen Idec and Abbott Present Positive Data for Daclizumab ... |
